A "2" way approach to business

The Cancer Health forecasts are very promising and are expected to grow at a rate which is higher than the world pharma market growth rate. The market is expected to reach a an approximate size of greater than US $ 75 Billion by the year  2011 according to IMS forecasts in the recent past.

1st approach-

This process highlights the potential growth of the pharma cancer pipeline primarily in new drug development. This of course would be subject to a lot many factors related to investments in their pipeline.  The drug development process for various Cancer trials are conducted with a goal of achieving all unmet needs of cancer patients. These involve a great deal of outsourcing to CRO's & trial sites owned/affiliated to CRO's. Veeda Oncology is a dedicated division of Veeda clinical research which has its dedicated trial sites in Europe, USA & India to cater to the outsourcing needs of cancer drug development programmes of global Pharma.

2nd approach-

All those branded cancer drugs going off patent would face market erosion from "generic biologics/ biosimilars".  The current health policies in the USA outlined by President Obama's government for cancer treatment for existing patients with known treatments for cancer control go in favor of  "generic biologics". 

Although the  laws are taking "shape" to outline" the safety profiles of generic biologics, the days are not far when the same would be available as cost effective bio-equivalent  and safe versions of their branded counterparts in the world.